Frizzled Homolog 10 (FZD10) Antibody (FITC)

Este producto es parte de FZD - Frizzled Homolog
Product Graph
169€ (20 µg)

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.

935106861
info@markelab.com
name
Frizzled Homolog 10 (FZD10) Antibody (FITC)
category
Primary Antibodies
provider
Abbexa
reference
abx335737

Description

FZD10 Antibody (FITC) is a Rabbit Polyclonal against FZD10.

Documents del producto

Instrucciones
Data sheet
Descargar

Product specifications

Category
Primary Antibodies
Immunogen Target
Frizzled Homolog 10 (FZD10)
Host
Rabbit
Reactivity
Human
Recommended Dilution
Optimal dilutions/concentrations should be determined by the end user.
Clonality
Polyclonal
Conjugation
FITC
Isotype
IgG
Purity
> 95%
Purification
Purified by Protein G.
Size 1
20 µg
Size 2
50 µg
Size 3
100 µg
Size 4
200 µg
Size 5
1 mg
Form
Liquid
Buffer
0.01 M PBS, pH 7.4, 0.03% Proclin-300 and 50% Glycerol.
Availability
Shipped within 5-10 working days.
Storage
Aliquot and store at -20°C. Avoid exposure to light. Avoid repeated freeze/thaw cycles.
Dry Ice
No
UniProt ID
Q9ULW2
Gene ID
11211
Alias
FZD10,Frizzled Homolog 10,Fz10,FzE7,CD350,FZ-10,hFz10,Frizzled class receptor 10
Background
Antibody anti-FZD10
Status
RUO

Descripción

FZD10 is a Wnt receptor predominantly mediating canonical Wnt/β-catenin signaling, playing crucial roles in embryogenesis, tissue regeneration, and tumor progression. It is highly expressed in the nervous system, skeletal tissues, and certain cancers. During development, FZD10 regulates processes like cell proliferation, differentiation, and tissue patterning, particularly in neural and skeletal systems. In cancer, FZD10 is overexpressed in tumors such as synovial sarcoma, colorectal cancer, and hepatocellular carcinoma, where it drives Wnt/β-catenin signaling to promote cell survival, proliferation, and metastasis. Its expression correlates with poor prognosis, therapy resistance, and enhanced tumor progression. FZD10 also plays roles in tissue repair and regeneration by regulating stem cell behavior and promoting cell renewal. Targeting FZD10 with monoclonal antibodies and small-molecule inhibitors is being explored as a therapeutic approach for Wnt-driven cancers, particularly synovial sarcoma. Dysregulation of FZD10 contributes to developmental defects, cancer metastasis, and tissue-specific diseases, highlighting its importance in both normal development and disease pathology.

Related Products

FNab03219

FZD10 antibody

Ver Producto
P2733

Recombinant Human FZD10

Ver Producto
abx015245

Frizzled Homolog 10 (FZD10) Antibody

Rabbit polyclonal antibody against FZD10 protein. Immunogen region is Internal.

Ver Producto